Novo Nordisk's AI Ambition and Workforce Whiplash

Novo Nordisk stock struggles as AI initiative GPT-Rosalind launches against a backdrop of revenue decline, patent expiry, and a major share buyback program.

Novo Nordisk shares, trading at €34.44, are caught in a strategic tug-of-war. The Danish pharmaceutical giant is simultaneously launching a major AI initiative while navigating one of its most severe revenue downturns in recent memory, with the stock down nearly 23% year-to-date and more than 50% below its June 2025 peak of €70.13.

This pressure follows a year of profound internal upheaval. In 2025, CEO Mike Doustdar’s sweeping cost-cutting program eliminated approximately 9,000 jobs, roughly 10% of the global workforce. In a stark reversal, the company has already hired 2,000 new employees this year, focusing recruitment squarely on core areas like production and research. This strategic realignment comes at a critical juncture for the beleaguered equity.

Financially, the headwinds are substantial. For the full 2026 fiscal year, management anticipates a revenue decline of between 5% and 13%. This forecast is pressured by intense competition in the lucrative weight-loss drug market, significant price discounts in the US, and looming patent expirations. In a key development, a crucial patent for the active ingredient semaglutid expired in China in March, opening the door for local generic manufacturers after a three-year legal defense by Novo Nordisk.

Amidst this challenging backdrop, the company is deploying capital to support its share price. A share buyback program worth 15 billion Danish kroner is underway, with the current tranche running until early May 2026. Technical indicators reflect the stock's strain, with a Relative Strength Index (RSI) reading of 25 signaling deeply oversold conditions.

On the innovation front, Novo Nordisk is betting heavily on artificial intelligence to reshape its future. On April 17-18, 2026, the company unveiled "GPT-Rosalind," a specialized AI model for biology and translational medicine developed in collaboration with OpenAI. The ambition is to drastically shorten the traditional 10-to-15-year drug development timeline. Internally, the model has reportedly outperformed 95% of human experts in predicting RNA sequences. Pilot programs are active across the value chain, with full integration targeted by the end of 2026.

The product pipeline offers some counterbalance to the financial concerns. The company recently launched a higher-dose Wegovy injection, with clinical data showing an average weight loss of around 21%. Furthermore, an oral formulation of Wegovy demonstrated a 14% average weight reduction over 64 weeks in a study, compared to 2.4% for placebo. Notably, about 28% of participants on the 25mg maintenance dose lost more than one-fifth of their body weight.

Independent research is also shedding new light on patient experiences. An April 2026 study published in Nature, using AI to analyze over 400,000 social media reports on GLP-1 drugs, confirmed gastrointestinal issues as the most common side effect at 37%. It also uncovered less-documented symptoms, including menstrual cycle changes for nearly 4% of female users.

All eyes are now on the upcoming quarterly report due on May 6. Investors will scrutinize the launch of the new Wegovy pill and any potential adjustments to the full-year outlook. Should guidance weaken further, the stock faces a potential test of key support around the €30 level. The central question remains whether the company's technological push and product launches can ultimately outweigh the formidable pricing and competitive pressures it currently faces.